An executive order on drug manufacturing, a controversial HHS appointee, a diabetes drug for prostate cancers, and more were this week’s top industry headlines.
Antibodies that are a fraction of the size of a regular antibody protect against key toxins in snake venom and could potentially replace 130-year-old treatments.